Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Arterial hypertension is linked to a higher epilepsy incidence.
• Animal studies suggest angiotensin receptor blockers (ARBs) may inhibit seizures.
• Clinical data on ARB therapy for epilepsy prevention in humans is limited.

Purpose of the Study:

• To investigate the association between ARB therapy and the incidence of epilepsy in hypertensive patients.
• To compare epilepsy incidence in patients treated with ARBs versus other antihypertensive drug classes.

Main Methods:

• A cohort study utilized data from the Disease Analyzer database (IQVIA) in Germany (2010-2020).
• Included were 168,612 adult patients with hypertension, matched using propensity scores across four drug classes: ARBs, beta-blockers, ACE inhibitors, and calcium channel blockers.
• Epilepsy incidence was the primary outcome, analyzed using Cox regression models.

Main Results:

• Patients receiving ARBs showed the lowest epilepsy incidence over 5 years (0.99%) compared to beta-blockers (1.47%) and calcium channel blockers (1.48%).
• ARB therapy was significantly associated with a decreased incidence of epilepsy (hazard ratio, 0.77; 95% CI, 0.65-0.90) compared to other antihypertensive drug classes.
• The study included over 1.5 million patients, with 42,153 in each propensity score-matched group.

Conclusions:

• Angiotensin receptor blocker therapy is associated with a significantly reduced incidence of epilepsy in patients with hypertension.
• These findings suggest that antihypertensive drugs, specifically ARBs, could represent a novel strategy for epilepsy prevention in hypertensive individuals.
• Further research is warranted to confirm these findings and explore the underlying mechanisms.